http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2007506792-A

Outgoing Links

Predicate Object
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02P20-55
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D305-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D409-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-337
classificationIPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07B53-00
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D305-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K-
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07F7-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D493-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-357
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-337
filingDate 2004-09-27-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2007-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber JP-2007506792-A
titleOfInvention 9,10-α, α-OH-taxane analogs and methods for their production
abstract The present invention relates to 9,10-α, α-OH taxane compounds and processes for their production. The present invention provides novel and useful compounds for use in the treatment of cancer. The present invention also provides intermediates used to form compounds useful for cancer therapy. The present invention also provides methods used to produce taxane analogs and derivatives thereof for use in treating cancer. The present invention contemplates a formulation for treating cancer in a patient, the formulation comprising a selected concentration of a taxane and a pharmaceutically acceptable carrier therefor.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2014512362-A
priorityDate 2003-09-25-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468160899
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467311709
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467275460
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467558461
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466985178
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID466522792
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467705300
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467724504
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467478511

Total number of triples: 35.